[Expert consensus on standardization of the management of primary liver cancer].
Ye
Sheng-long
SL
Chinese Societies of Liver Cancer and Clinical Oncology, Chinese Anti-Cancer Association. slye@shmu.edu.cn
D001557:Benzenesulfonates / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis* / Q000628:therapy*; D017115:Catheter Ablation / Q000379:methods; D016461:Chemoembolization, Therapeutic; D003226:Congresses as Topic; D006498:Hepatectomy / Q000379:methods*; D006499:Hepatic Artery; D006801:Humans; D016031:Liver Transplantation; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000628:therapy*; D009367:Neoplasm Staging; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D017410:Practice Guidelines as Topic; D011725:Pyridines / Q000627:therapeutic use; D020266:Radiotherapy, Conformal; D000077157:Sorafenib; D014463:Ultrasonography; D000509:alpha-Fetoproteins / Q000032:analysis
D001557:Benzenesulfonates; D015415:Biomarkers; D010671:Phenylurea Compounds; D011725:Pyridines; D000509:alpha-Fetoproteins; D009536:Niacinamide; D000077157:Sorafenib